The immunodeficient status of leukemia patients affected by AML could be related to the ability of malignant ROS-producing myeloid clones to activate parthanatos through the ERK1/2/PARP-1 axis in NK lymphocyte populations [185,186]. Here, PARP1 is linked to acute myeloid leukemia.